Reviews:
Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
Metrics: PDF 3074 views | HTML 7089 views | ?
Abstract
Yiping Wen1,*, Jing Cai1,*, Yaya Hou1, Zaiju Huang1 and Zehua Wang1
1 Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
* These authors have contributed equally to this work
Correspondence to:
Zehua Wang, email:
Keywords: EZH2, cancer stem cells, sphere, histone lysine methylation, polycomb repressive complex
Received: November 02, 2016 Accepted: March 02, 2017 Published: March 22, 2017
Abstract
Epigenetic modifications in cancer stem cells largely result in phenotypic and functional heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly expressed in cancer stem cells of numerous malignant tumors and has a critical function in cancer stem cell expansion and maintenance. Here, we review up-to-date information regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem cells in various malignant tumors and discuss the therapeutic potential of targeting EZH2 in tumors.
![Creative Commons License](/images/80x15.png)
PII: 16467